永安药业
(002365)
| 流通市值：32.03亿 | | | 总市值：38.49亿 |
| 流通股本：2.45亿 | | | 总股本：2.95亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 235,897,297 | 783,167,007.89 | 577,148,711.33 | 367,377,098.49 |
| 营业收入 | 235,897,297 | 783,167,007.89 | 577,148,711.33 | 367,377,098.49 |
| 二、营业总成本 | 226,434,212.68 | 791,244,833.8 | 586,972,011.53 | 373,906,890.49 |
| 营业成本 | 188,175,215.05 | 650,684,052.19 | 478,752,909.74 | 309,288,489.16 |
| 税金及附加 | 3,083,096.09 | 10,030,751.49 | 7,525,479.51 | 5,115,003.65 |
| 销售费用 | 9,228,146.66 | 40,065,902.58 | 31,798,297.87 | 14,587,095.68 |
| 管理费用 | 14,407,352.39 | 59,700,447.16 | 44,042,372.41 | 29,255,363.87 |
| 研发费用 | 8,622,162.46 | 30,876,613.76 | 26,082,917.32 | 17,358,750.95 |
| 财务费用 | 2,918,240.03 | -112,933.38 | -1,229,965.32 | -1,697,812.82 |
| 其中:利息费用 | 10,397.51 | 941,505.85 | 738,453.53 | 520,720.37 |
| 其中:利息收入 | 124,134.13 | 1,357,016.04 | 923,207.65 | 633,205.18 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,507,210.49 | -1,085,650.93 | 85,800.14 | 2,004,491.16 |
| 加:投资收益 | 5,242,302.15 | 30,560,208.94 | 25,322,485.07 | 11,461,930.22 |
| 资产处置收益 | -33,352.93 | 185,682.47 | 52,495.68 | 32,631.44 |
| 资产减值损失(新) | -3,242.04 | -16,527,392.86 | -822,527.84 | -444,891 |
| 信用减值损失(新) | -1,654,458.36 | 124,223.68 | 822,783.62 | 1,470,540.52 |
| 其他收益 | 647,764.19 | 5,470,623.02 | 2,599,789.12 | 1,701,484.47 |
| 四、营业利润 | 10,154,886.84 | 10,649,868.41 | 18,237,525.59 | 9,696,394.81 |
| 加:营业外收入 | 18,716.03 | 307,044.1 | 589,194.56 | 295,984.95 |
| 减:营业外支出 | 1,014,713.61 | 1,079,022.86 | 806,265.26 | 511,411.57 |
| 五、利润总额 | 9,158,889.26 | 9,877,889.65 | 18,020,454.89 | 9,480,968.19 |
| 减:所得税费用 | 1,170,176.54 | 2,687,825.14 | 1,678,334.1 | 924,809.5 |
| 六、净利润 | 7,988,712.72 | 7,190,064.51 | 16,342,120.79 | 8,556,158.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 7,988,712.72 | 7,190,064.51 | 16,342,120.79 | 8,556,158.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 7,736,703.46 | 22,493,429.92 | 25,496,259.56 | 12,495,723.72 |
| 少数股东损益 | 252,009.26 | -15,303,365.41 | -9,154,138.77 | -3,939,565.03 |
| 扣除非经常损益后的净利润 | 7,250,939.13 | -2,441,923.78 | 5,184,418.3 | 2,285,336.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.08 | 0.09 | 0.04 |
| (二)稀释每股收益 | 0.03 | 0.08 | 0.09 | 0.04 |
| 八、其他综合收益 | -114,894.12 | -170,283.48 | -86,818.37 | -31,790.91 |
| 归属于母公司股东的其他综合收益 | -114,894.12 | -170,283.48 | -86,818.37 | -31,790.91 |
| 九、综合收益总额 | 7,873,818.6 | 7,019,781.03 | 16,255,302.42 | 8,524,367.78 |
| 归属于母公司股东的综合收益总额 | 7,621,809.34 | 22,323,146.44 | 25,409,441.19 | 12,463,932.81 |
| 归属于少数股东的综合收益总额 | 252,009.26 | -15,303,365.41 | -9,154,138.77 | -3,939,565.03 |
| 公告日期 | 2026-04-30 | 2026-04-17 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |